B of A Securities Maintains Buy on LENZ Therapeutics, Lowers Price Target to $29

Benzinga Newsdesk www.benzinga.com Neutral 46.3%

Neg 0% Neu 46.3% Pos 0%

B of A Securities analyst Jason Gerberry maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $35 to $29.